Vivos Therapeutics ( (VVOS) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vivos Therapeutics, Inc. has filed a Form 12b-25 indicating a delayed Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The late filing relates specifically to its annual Form 10-K (Yearly Report).
The company cites the complexity of compiling and reviewing information tied to its 2025 acquisition of The Sleep Center of Nevada as the main reason for the delay. Additional time is needed to finalize year-end financial statements and related disclosures linked to that sleep center business.
Vivos Therapeutics, Inc. states that it expects to submit the Form 10-K (Yearly Report) within the standard 15-day extension window allowed under SEC rules. Investors should therefore anticipate the filing in mid-April, assuming the company stays on its stated timeline.
Management is signaling notable changes in its 2025 financials versus 2024, including a revenue increase of more than 15% driven largely by higher sleep center testing and related Vivos treatments. However, a roughly 50% rise in sales, general and administrative expenses tied to running the sleep center operations is expected to widen the company’s net loss.
The company stresses that these figures are preliminary and may change once the audit and review process is complete, making them forward-looking in nature. Vivos Therapeutics, Inc. emphasizes its ongoing efforts to complete the Form 10-K (Yearly Report) and maintain reporting compliance, with the notification signed by Chief Financial Officer Bradford Amman on March 31, 2026.
The most recent analyst rating on (VVOS) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.
Spark’s Take on VVOS Stock
According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, worsening cash burn, and a more pressured balance sheet) and bearish technical signals (price below key moving averages with negative MACD). Offsetting factors include strong recent revenue growth and a strategic pivot highlighted on the earnings call, but ongoing cost escalation and the need for bridge/equity financing keep risk elevated, while valuation offers limited support due to negative earnings and no dividend.
To see Spark’s full report on VVOS stock, click here.
More about Vivos Therapeutics
Average Trading Volume: 127,507
Technical Sentiment Signal: Sell
Current Market Cap: $11.41M
Learn more about VVOS stock on TipRanks’ Stock Analysis page.